EUCTR2015-004112-38-ES进行中（未招募）1 期
An Open-Label Study of Brentuximab Vedotin+Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 59
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Main Criteria for Inclusion:
- •Male or female patients aged 5 to <18 years with newly diagnosed classical CD30+ advanced stage (Stage III and Stage IV) HL who are treatment naïve with Karnofsky Performance Status or Lansky Play-Performance =50.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 61
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Main Criteria for Exclusion:
- •Patients may not have nodular lymphocyte-predominant HL, known active cerebral meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy (PML) or any history of PML, sensory or motor peripheral neuropathy, or known hypersensitivity to brentuximab vedotin or any component of AVD.
研究者
相似试验
进行中（未招募）
1 期
Brentuximab vedotin+Adriamycin, vinblastine, and dacarbazine in pediatric patients with advanced stage newly diagnosed Hodgkin lymphomaCTIS2023-506415-18-00Takeda Development Center Americas Inc.59
进行中（未招募）
1 期
Brentuximab vedotin+Adriamycin, vinblastine, and dacarbazine in pediatric patients with advanced stage newly diagnosed Hodgkin lymphomaHodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells.The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a =50 Lansky Play-Performance or Karnofsky Performance Status.MedDRA version: 19.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2015-004112-38-ITMillennium Pharmaceuticals Inc.59
尚未招募
2 期
A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)Cancer2024-511567-28-01Kooperativni Lymfomova Skupina z.s.33
进行中（未招募）
1 期
Phase 4 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Not Suitable for Stem Cell Transplantation or Multiagent ChemotherapyRelapsed or Refractory Hodgkin LymphomaMedDRA version: 20.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-000232-10-DEMillennium Pharmaceuticals, Inc60
进行中（未招募）
1 期
Phase 4 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Not Suitable for Stem Cell Transplantation or Multiagent ChemotherapyRelapsed or Refractory Hodgkin LymphomaMedDRA version: 16.0Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-000232-10-ESMillennium Pharmaceuticals, Inc60